advertisement
Abstract #11301 Published in IGR 6-3
Impact of prostaglandin-F2α-analogues and carbonic anhydrase inhibitors on central corneal thickness -- a cross-sectional study on 403 eyes
Viestenz A; Martus P; Schlotzer-Schrehardt U; Langenbucher A; Mardin CYKlinische Monatsblätter für Augenheilkunde 2004; 221: 753-756
BACKGROUND: Histological changes of, in particular, collagen and extracellular matrix after administration of topical prostaglandin F2α(PGF (2α)) analogues have been reported. In view of this observation, we investigated the influence of PGF2α analogues on the central corneal thickness. PATIENTS AND METHODS: In a non-randomized, controlled, cross-sectional study, 403 eyes from 208 consecutive patients were examined: 149 eyes (normals/controls) and 79 with ocular hypertension (OHT), 119 eyes with primary open angle glaucoma (POAG) and 56 eyes with normal tension glaucoma (NTG). One experienced ophthalmologist measured the central corneal thickness (CCT) using ultrasound pachymetry (Tomey AL-2000, sequence of 5 measurements with an SD < 3 μm). The central corneal power was measured with the Zeiss keratometer. Depending on the topical treatment, the patients were classified into 4 groups: A) PGF2α analogues (n = 78), B) carbonic anhydrase inhibitors (n = 26), C) combination of PGF2α analogues and carbonic anhydrase inhibitors (n = 41), D) none of these drugs (n = 258). T tests and multiple linear regression analyses were used for statistical analysis. RESULTS: CCT was decreased significantly (p < 0.01 each) in eyes treated with PGF2α analogues (group A: 529 ± 34 μm), in comparison with the untreated and non-glaucomatous eyes (part of group D: 542 ± 35 μm, n = 148), untreated glaucomatous/OHT eyes (part of group D: 563 ± 37 μm, n = 110), eyes treated with carbonic anhydrase inhibitors (group B: 561 ± 32 μm) and eyes with a topical application of both PGF2α analogues and carbonic anhydrase inhibitors (group C: 555 ± 48 μm. No correlation was found between CCT and diagnosis (OHT, POAG, NTG, control), gender, central corneal power, and intraocular pressure in a multivariate analysis. CONCLUSIONS: The present findings suggest that the topical application of prostaglandin F2α analogues onto the cornea reduces the central corneal thickness significantly. These changes might be attributed to effects of PGF2α analogues on the extracellular matrix of the corneal stroma via upregulation of matrix metalloproteinases. In clinical practice, corneal thinning under local PGF2α analogue treatment could result in underestimation of intraocular pressure levels as measured by applanation tonometry. LA: German
Dr. A. Viestenz, Augenklinik mit Poliklinik der Universität Erlangen-Nürnberg. Arne.Viestenz@t-online.de
Classification:
2.2 Cornea (Part of: 2 Anatomical structures in glaucoma)
11.4 Prostaglandins (Part of: 11 Medical treatment)
11.5.2 Topical (Part of: 11 Medical treatment > 11.5 Carbonic anhydrase inhibitors)
